Physician profile
Kendra Phillis
NPI 1942868666
$4,047.02
in general payments reported to CMS, 2019-2025
16 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $273 · 2021: $424 · 2022: $1,078 · 2023: $706 · 2024: $1,196 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122 · Consulting Fee: $675 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.41 |
| Consulting Fee | $675.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $337.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,349.83 | 2019-2024 | Air Optix, Total30, Precision 1 |
| Coopervision INC. | $946.47 | 2020-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $717.16 | 2020-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $341.80 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $182.43 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $145.92 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $113.04 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $76.72 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $44.44 | 2022-2023 | |
| Lkc Technologies, INC. | $26.83 | 2024 | |
| Abbvie INC. | $22.11 | 2022 | |
| Aerie Pharmaceuticals, INC. | $20.66 | 2019 | |
| Thea Pharma INC. | $17.91 | 2024 | Iyuzeh |
| Harrow Eye, LLC | $14.23 | 2024 | Vevye |
| Quidel Corporation | $13.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $13.57 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Phillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.